Lower Limb Function After Spinal Cord Injury

Overview

This is a randomized, experimental study that examines the physiology of central nervous system pathways contributing to the control of bilateral movements in individuals with spinal cord injuries and promotes the recovery of lower-limb motor function through the use of stimulation and locomotor training.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: March 9, 2021

Detailed Description

This study plans to examine plasticity in corticospinal synapses of lower-limb muscles. it has been demonstrated that plasticity elicited at corticospinal synapses in the spinal cord result in enhancements in electromyographic (EMG) and force activity in upper-limb muscles. The first step in this proposal is to determine if synaptic plasticity can be elicited in corticospinal projections targeting lower-limb muscles in humans with SCI. We will also study methods to strengthen corticospinal plasticity to promote recovery of leg clearance during training. We will use two novel strategies to enhance plasticity in corticospinal synapses of lower-limb muscles after SCI: a). administration of an N-methyl-D-aspartate (NMDA) receptor agonist (i.e. D-cycloserine), and b). Combine NMDA-induced corticospinal plasticity with training (2D lower limb training and locomotor training. Corticospinal synaptic plasticity is thought to depend on activation of NMDA receptors and D-cycloserine enhances motor skill behaviors in animals and humans will be enhanced by NMDA-induced corticospinal plasticity. An important strength of this aim is the combination of training and strategies that aimed at enhancing the synaptic efficacy of residual corticospinal projections. Training effects on physiological pathways will be explored and correlated with locomotor function

Interventions

  • Drug: D-Cycloserine
    • 100 mg of Seromycin by mouth will be administered
  • Drug: Placebo
    • placebo pill will be administered instead of medication by mouth
  • Other: Training
    • walking around a designated track at different speeds both forward and backward
  • Other: Stimulation
    • magnetic stimulation and electrical stimulation may be applied
  • Other: Placebo Stimulation
    • this is a fake stimulation that is administered but will be unknow to the subject.

Arms, Groups and Cohorts

  • Active Comparator: D-Cycloserine/Placebo + Stimulation
    • Participant will be given a single dose of 100 mg of D-Cycloserine or placebo before receiving stimulation.
  • Active Comparator: Training+Med/Placebo+Stimulation
    • Participant will be given a single dose of 100 mg of D-Cycloserine or placebo before receiving stimulation followed by training.
  • Active Comparator: Training+Med+Stimulation/Placebo Stim
    • Participant will be given a single dose of 100 mg of D-Cycloserine or placebo before receiving stimulation or placebo stimulation followed by training.

Clinical Trial Outcome Measures

Primary Measures

  • Changes in motor evoked potential size
    • Time Frame: 30 minutes before and 30 minutes after intervention

Participating in This Clinical Trial

Inclusion Criteria

  • 4. Inclusion criteria for individuals with SCI: – Male and females between ages 18-85 years of age – SCI ( ≥1 month of injury) – ASIA A, B,C and D – SCI above L5 – Able to perform a visible contraction with dorsiflexor and hip flexor muscles (allowing testing of largely impaired patients) – Able to ambulate a few steps with or without an assistive device Inclusion criteria for healthy controls: – Male and females between ages 18-85 years of age – Able to walk and complete lower-limb tests with both legs Exclusion Criteria:

Exclusion criteria for individuals with SCI

  • Uncontrolled medical problems including pulmonary, cardiovascular or orthopedic disease, – Any debilitating disease prior to the SCI that caused exercise intolerance – Premorbid, ongoing major depression or psychosis, altered cognitive status – History of head injury or stroke, – Metal plate in skull – History of seizures – Receiving drugs acting primarily on the central nervous system, which lower the seizure threshold such as antipsychotic drugs (chlorpromazine, clozapine) or tricyclic antidepressants. – Pregnant females, and – Ongoing cord compression or a syrinx in the spinal cord or who suffer from a spinal cord disease such as spinal stenosis, spina bifida or herniated cervical disk. Exclusion criteria for healthy controls: – Uncontrolled medical problems including pulmonary, cardiovascular or orthopedic disease, – Any debilitating disease that causes exercise intolerance – Premorbid, ongoing major depression or psychosis, altered cognitive status – History of head injury or stroke, – Metal plate in skull – History of seizures – Receiving drugs acting primarily on the central nervous system, which lower the seizure threshold such as antipsychotic drugs (chlorpromazine, clozapine) or tricyclic antidepressants. – Pregnant females, and – Ongoing cord compression or a syrinx in the spinal cord or who suffer from a spinal cord disease such as spinal stenosis, spina bifida or herniated cervical disk.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 85 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Shirley Ryan AbilityLab
  • Collaborator
    • The Craig H. Neilsen Foundation
  • Provider of Information About this Clinical Study
    • Principal Investigator: Monica Perez, Chair Arms + Hands Lab – Shirley Ryan AbilityLab
  • Overall Official(s)
    • Monica A Perez, PT, Phd, Principal Investigator, Shirley Ryan AbilityLab

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.